在线音乐收入增长超预期 ——云音乐（9899.HK）24H1 点评 核心观点 ⚫ 24H1 营收 40.7 亿(yoy+4.1%, hoh+3%)，主要系会员订阅收入因付费会员数增长 提升。我们预期 24H2 达 40 亿（yoy+1%），主要系直播业务首页流量权重调整影 响。24H1 毛利率 35%（yoy+10pp，hoh+6pp），主要系业务规模的扩大、核心在 线音乐业务的强劲商业化表现带来经营杠杆持续提效，以及版权成本的一次性调 整。 24H1 销售费用 4 亿(yoy-0%,hoh-5%)。24H1 管理费用 0.9 亿 (yoy+24%,hoh3%)，主要系僱员福利费用增加。24H1 研发费用 4 亿 (yoy-10%,hoh-8%)。主要系 技术资源利用率提高。 24H1 归母净利润（IFRS）8.1 亿（yoy+176%,hoh+84%)， 我们预期盈利能力随着会员收入提升持续优化。 ⚫ 24H1 在线音乐收入 26 亿(yoy+27%, hoh+10%)，主要系在线音乐月付费用户增 加，如持续致力拓宽与音乐版权方的合作，完善了平台的韩国音乐内容库，并与音 乐厂牌建立深入的伙伴关系等。我们预期 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected price increase of over 15% within the next 6-12 months [3][7]. Core Insights - The company reported a strong revenue growth of 55% year-on-year in 1H24, driven by the success of its commercial products, particularly the drug Dabrushe (Sintilimab) [2][3]. - The gross margin improved by 1.6 percentage points to 82.9%, attributed to increased production and ongoing cost optimization [3]. - The company is expanding its commercial product offerings, with expectations to increase the number of commercialized products to 12 by the end of the year [3]. Financial Summary - **Revenue Growth**: The company’s revenue is projected to grow from 6,206 million RMB in 2023 to 7,823 million RMB in 2024, reflecting a growth rate of 26.05% [1]. - **Net Profit**: The net profit is expected to improve significantly, moving from a loss of 1,028 million RMB in 2023 to a loss of 524 million RMB in 2024, with a forecasted profit of 1,098 million RMB by 2026 [1]. - **Earnings Per Share (EPS)**: The diluted EPS is projected to improve from -0.63 RMB in 2023 to 0.09 RMB in 2025, and further to 0.67 RMB in 2026 [1]. - **Return on Equity (ROE)**: The ROE is expected to turn positive by 2025, reaching 1.23% and further increasing to 8.29% by 2026 [1]. Research and Development - The company has six New Drug Applications (NDAs) currently under review by the National Medical Products Administration, with significant advancements in the cardiovascular and metabolic (CVM) fields [3]. - The company has multiple late-stage clinical projects making milestone progress, with several innovative pipelines showing promising preliminary data [3].

Investment Rating - The report maintains a "Buy" rating for the company, with an expected price increase of over 15% in the next 6-12 months [21][17] Core Views - The company's Q2 2024 performance exceeded expectations, with revenue reaching RMB 82.3 billion, a 21% YoY increase, and Non-IFRS net profit of RMB 13.6 billion, up 77.6% YoY [12] - Local core commerce revenue grew 18.5% YoY to RMB 60.7 billion, with operating profit increasing 36.8% YoY to RMB 15.2 billion, and operating margin improving by 3.3 percentage points to 25.1% [12] - New business revenue increased 28.7% YoY to RMB 21.6 billion, with operating losses narrowing by 74.7% to RMB 1.3 billion, and the loss ratio improving by 24.9 percentage points YoY [13] Business Segments Food Delivery and Instant Retail - Food delivery and instant retail saw a 14.2% YoY increase in daily orders, reaching 67.77 million, with total transaction volume hitting 6.167 billion in Q2 2024 [12] - The "Pinhao Fan" service achieved a record daily order peak of 8 million, driven by affordable offerings that lowered the threshold for user orders and improved retention [12] - Flash delivery expanded its coverage, with the self-operated alcohol retail brand "Waima Songjiu" continuing to grow, and online medical insurance payments for non-prescription drugs driving growth in the healthcare category [12] In-Store and Hotel & Travel - In-store and hotel & travel business saw order volume grow over 60% YoY, with record-high annual transacting users and active merchants [12] - Leisure and entertainment categories experienced over 60% YoY growth in GTV and order volume, while beauty and medical aesthetics categories saw GTV growth exceeding 50% [12] - The "Shen Membership" system was upgraded and extended to the in-store and hotel & travel categories, enhancing the company's brand as a value-for-money platform [12] New Businesses - Meituan Select improved product quality and pricing through enhanced supply chain management, driving overall operational efficiency [13] - Xiaoxiang Supermarket led industry growth with continuous efficiency improvements, while B2B food supply chain services, restaurant management systems, and shared mobility services also achieved healthy growth [13] Financial Projections - Revenue is projected to reach RMB 3.357 trillion, RMB 3.874 trillion, and RMB 4.410 trillion in 2024, 2025, and 2026, respectively [13] - Non-IFRS net profit is expected to be RMB 40.5 billion, RMB 50.0 billion, and RMB 65.8 billion for 2024, 2025, and 2026, respectively [13] - The P/E ratio is forecasted at 14.47x, 11.72x, and 8.90x for 2024, 2025, and 2026, respectively [13] Valuation Metrics - The company's ROE (Return on Equity) is expected to improve significantly, from 9.11% in 2023 to 20.11% in 2026 [23] - The P/B (Price-to-Book) ratio is projected to decline from 4.21 in 2023 to 2.28 in 2026, indicating improving valuation metrics [23]

Investment Rating - The report maintains a "Buy" rating for the company, expecting significant growth in the next 6-12 months [1] Core Views - The company achieved a strong performance in 1H24 with revenue of RMB 2.04 billion, up 48% YoY, and a net profit of RMB 10.91 million, turning from a loss to profit [1] - The company's adjusted EBITDA reached RMB 230 million, an 84% increase YoY, indicating improved operational efficiency [1] - The company opened 146 new stores in 1H24, exceeding expectations and completing 61% of its annual store opening plan [1] - Same-store sales grew by 3.6% YoY, with daily sales per store reaching RMB 13,515, up 10.1% YoY, reflecting strong product and brand momentum [1] - The company's restaurant-level operating profit margin improved to 14.5%, up 1.0 percentage point YoY, driven by cost optimization and scale effects [1] Financial Performance - The company's revenue is expected to grow from RMB 4.28 billion in 2024E to RMB 6.95 billion in 2026E, with a CAGR of 28.01% [3] - Net profit is projected to increase from RMB 19 million in 2024E to RMB 199 million in 2026E, with a significant growth rate of 359.25% [3] - The company's adjusted net profit is forecasted to grow from RMB 110 million in 2024E to RMB 320 million in 2026E, with a CAGR of 95% [1] - The company's ROE is expected to improve from 0.91% in 2024E to 8.44% in 2026E, indicating enhanced profitability [3] Store Expansion and Operational Efficiency - The company expanded its store network to 914 stores by the end of 1H24, covering 33 cities, with 31 new stores opened and 29 under construction as of August 2024 [1] - The company's store-level operating profit margin improved to 14.5%, driven by cost control and scale effects, with key cost items such as raw materials and rent showing favorable trends [1] - The company's adjusted EBITDA margin increased to 11.4%, up 2.2 percentage points YoY, reflecting improved operational efficiency [1] Market Position and Growth Potential - The company holds a competitive advantage in the pizza category and is in a rapid store expansion phase, with strong growth potential in both existing and new markets [1] - The company's same-store sales growth and store-level profitability improvements demonstrate its ability to perform well even in a challenging market environment [1] - The company's expansion into new cities, such as Jiangmen, Taizhou, Jinhua, and Huizhou, is expected to further drive sales growth and market penetration [1]

Investment Rating - The investment rating for the company is "Buy" (maintained) [2][8] Core Views - The company has a stable investment outlook with ample land reserves, maintaining its annual sales target. The mid-term dividend payout ratio remains stable. The company reported a revenue growth of 10.1% year-on-year for the first half of 2024, despite a decline in net profit by 15.9% [2][3] - The company’s gross margin is under pressure, decreasing by 4.1 percentage points year-on-year to 13.7%. The operating cash flow for the first half of 2024 was 61.3 billion, with cash at the end of the period amounting to 481.4 billion, an increase of 4.4% from the beginning of the year [2][3] - The company achieved a contract sales amount of 554.0 billion, a decrease of 33.8% year-on-year, but improved its sales ranking to 9th place. The sales target for the year remains unchanged at 1,470 billion [2][3] - The company has diversified its land acquisition strategies, adding 12 plots of land with a total construction area of 1.72 million square meters, focusing on high-tier cities. The total land reserve is 25.03 million square meters, with significant portions in the Greater Bay Area and Guangzhou [2][3] - The company’s commercial properties generated rental income of 297 million, a year-on-year increase of 41.3%. The average financing cost decreased by 41 basis points to 3.57% [2][3] Financial Summary and Valuation Indicators - For the first half of 2024, the company reported revenue of 353.4 billion, net profit of 18.3 billion, and core net profit of 17.4 billion. The expected net profits for 2024-2026 are projected at 35.2 billion, 39.7 billion, and 44.3 billion respectively, with corresponding EPS of 0.88, 0.99, and 1.10 [3][4] - The company’s P/E ratios for 2024, 2025, and 2026 are projected at 4.0, 3.5, and 3.2 respectively, indicating a favorable valuation compared to earnings growth [3][4]

中国海外发展 销售市占率逆势提升，商业物业收入保持增长 （00688.HK） 2024 年 08 月 29 日 投资评级：买入（维持） | --- | --- | |--------------------|---------------| | 日期 | 2024/8/28 | | 当前股价(港元) | 11.640 | | 一年最高最低(港元) | 18.340/10.100 | | 总市值(亿港元) | 1,273.98 | | 流通市值(亿港元) | 1,273.98 | | 总股本(亿股) | 109.45 | | 流通港股(亿股) | 109.45 | | 近 3 个月换手率(%) | 10.35 | 股价走势图 中国海外发展 恒生指数 -40% -30% -20% -10% 0% 10% 2023-08 2023-12 2024-04 数据来源：聚源 相关研究报告 《营收利润双增，核心城市补仓坚守 高质量发展—公司信息更新报告》 -2024.3.29 《三季度业绩增长，一线城市拿地力 度加大 — 公 司 信 息 更 新 报 告 》 -2023.10.27 《权益销售金额排名榜首，核心城市 土 储 ...

Investment Rating - Maintains an "Overweight" rating for the company [2] Core Views - The company's capital expenditure has significantly decreased, leading to a substantial year-on-year decline in BOT construction revenue, resulting in fluctuations in the 2024 interim performance [4] - Operations remain stable, with water treatment business volume and prices increasing [4] - High dividend payout ratio with stable dividend distribution [4] Financial Performance - 2024 H1 revenue: 11.309 billion RMB, down 6% year-on-year [4] - 2024 H1 net profit attributable to shareholders: 1.122 billion RMB, down 18% year-on-year [4] - Construction service revenue: 1.642 billion RMB, down 49% year-on-year [4] - Operating income from sewage and water supply services showed steady growth [4] Water Treatment Business - Total water treatment design capacity: 44 million tons/day as of H1 2024 [4] - Sewage: 24.84 million tons/day - Water supply: 14.34 million tons/day - Recycled water: 4.52 million tons/day - Seawater desalination: 0.3 million tons/day - Sewage treatment volume increased by 5% year-on-year [4] - Average sewage treatment contract price: 1.51 RMB/ton, slightly up from 1.49 RMB/ton in 2023 [4] - Sewage treatment gross margin improved by 2 percentage points to 59% [4] - Water supply volume increased by 4% year-on-year [4] - Average water supply contract price: 2.16 RMB/ton, slightly up from 2.15 RMB/ton in 2023 [4] - Water supply gross margin decreased by 4 percentage points to 43% [4] BOT Construction - BOT construction revenue: 1.258 billion RMB, down 57% year-on-year [4] - Focus on light-asset projects, reducing investment in BOT water projects [4] Capital Expenditure and Dividends - 2024 H1 capital expenditure: 1.573 billion RMB, significantly down from 3.618 billion RMB in the same period last year [4] - Interim dividend: 0.07 HKD per share, same as last year, with a cash dividend payout ratio of 60% [4] - Trailing twelve-month (TTM) dividend yield: 7.04% [4] Market Data - Current price: 2.23 HKD [5] - 52-week price range: 1.50-2.78 HKD [5] - Current shares outstanding: 10,047 million [5] - Current market capitalization: 22,404 million HKD [5] Financial Forecast - 2024-2026 forecasted net profit: 1.966 billion, 2.040 billion, and 2.150 billion RMB respectively [4] - 2024-2026 forecasted EPS: 0.20, 0.20, and 0.21 RMB respectively [4]

2024 年 8 月 27 日 中广核矿业（1164.HK） 海外矿山收益大幅增长，分红税政策变动影响净利 事件：中广核矿业公布 2024 年上半年业绩，公司实现营收 40.73 亿港元，税前 利润 3.24 亿港元，同比上升 37.5%；净利润 1.13 亿港元，同比下降 37.1%。因 上半年国际铀价维持高位及海外矿山成本优势，其投资收益增长亮眼，但因受 到哈国税收政策变动，补交过往三年税费导致所得税大幅上升，影响净利润。但 公司作为行业稀有标的，在国内核电大发展背景及天然铀量价共升推动下，看 好公司未来业绩长期发展，维持"买入"评级。 报告摘要 上半年税前利润同比增加 37.5%，受海外税收变动影响净利降幅较大 2024 年上 半年公司实现营收 40.73 亿港元，实现税前利润 3.24 亿港元，同比上升 37.5%； 实现净利润 1.13 亿港元，同比下降 37.1%；实现每股基本盈利 1.49 港仙，同比 下降 37%。公司上半年净利润下降由于所得税费用大幅上升，上半年所得税费用 达 2.1 亿港元，同比增加 278%，其原因为哈国协定税率优惠适用口径收紧后， 公司因审慎考虑补缴 2020-23 年 ...

Investment Rating - The report maintains a "BUY" rating for BYDE with a target price of HK$45.28, indicating a potential upside of 53% from the current price of HK$29.50 [4][14][20]. Core Insights - BYDE reported a strong revenue growth of 40% year-on-year for 1H24, driven by increased market share in the Apple segment, recovery in the Android market, integration with Jabil, and robust performance in the New Energy Vehicle (NEV) sector [2][3]. - Despite the strong revenue growth, net profit only increased by 0.1% year-on-year, falling short of expectations due to a 1 percentage point decline in gross profit margin and a significant increase in sales expenses by 211% [2][3]. - The outlook for 2H24 remains positive, with expectations of strong revenue growth driven by the iPhone/iPad upgrade cycle, solid Android demand, and contributions from AI server products [3][14]. Financial Summary - For FY24E, revenue is projected to reach RMB 171.96 billion, with a year-on-year growth of 32.3%. Net profit is expected to be RMB 5.06 billion, reflecting a growth of 25.3% [6][16]. - The report highlights a decrease in gross profit margin to 6.8% in 1H24, down from the previous year, while sales expenses surged to RMB 902 million [3][6]. - The company is expected to see a recovery in gross profit margin in 2H24, with interest expenses projected to decrease significantly as BYDE transitions from USD loans to RMB loans [3][14]. Revenue Breakdown - Revenue from assembly, components, and new smart products showed significant year-on-year growth, with assembly and components growing by 36% and 206% respectively, while new smart products experienced a decline of 16% [6][16]. - The NEV segment is anticipated to continue driving growth, supported by new product launches and increasing market demand [3][14]. Valuation Metrics - The report assigns a P/E ratio of 18.3x for the target price calculation, with assembly and components businesses valued at 15x, reflecting their recovery potential and market positioning [14][20]. - The report also notes a projected P/B ratio of 2.5x for FY24E, indicating a favorable valuation relative to peers [14][20].

Investment Rating - The report assigns a "BUY" rating to the company, indicating a potential return exceeding 15% over the next 12 months [15]. Core Insights - The company reported strong growth in innovative drug sales, with a revenue of 6.51 billion RMB in the first half of the fiscal year 2024, including a 185 million USD upfront payment from GSK related to the licensing of HS-20093 [1]. - The innovative drug sales accounted for 77% of total revenue, with a year-on-year growth of 31.6% when excluding collaboration revenue [1]. - The company plans to distribute approximately 40% of its net profit of 2.73 billion RMB as dividends [1]. - The target price for the company's stock has been raised to HK$24.11 from HK$22.06, reflecting a 17% upside from the current price of HK$20.60 [1]. Financial Performance - For FY24E, the company expects total revenue to grow by 21% to 12.23 billion RMB, with organic revenue growth projected at 14.3% and 14.1% for FY24E and FY25E, respectively [3][4]. - The net profit is expected to increase by 33.3% to 4.37 billion RMB in FY24E, followed by a decrease of 25.1% in FY25E [4][12]. - The company has improved cost efficiency, with sales expense ratio decreasing to 33.7% from 37.5% in FY23 [1]. Product Pipeline and Growth Drivers - The company is expanding the indications for aumolertinib, with new drug applications accepted for postoperative adjuvant therapy and maintenance treatment for locally advanced unresectable non-small cell lung cancer [1]. - Aumolertinib's sales are expected to grow by 22% by the end of FY24, reaching 438 million RMB, with a target of 600 million RMB by 2026 [1]. - The company is also advancing its ADC pipeline, with HS-20093 showing promising early signals in clinical trials for small cell lung cancer [3]. Market Position and Competitive Landscape - As an early entrant in the third-generation EGFR-TKI market in China, the company is well-positioned to capture market share with its innovative products [1]. - The company is expected to submit another NDA for aumolertinib in combination with chemotherapy in Q4 2024, differentiating itself from domestic competitors [1]. Valuation Metrics - The report provides a DCF valuation with a target price of HK$24.11, based on a weighted average cost of capital of 8.52% and a terminal growth rate of 3.5% [5][7]. - The company's P/E ratio is projected to be 25.6x for FY24E, reflecting a strong growth outlook [12].